From GlobeNewswire: 2025-05-19 02:30:00

Alvotech, a global biotech company, announced the outcome of the offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm. The Offering attracted strong interest and was multiple times oversubscribed. Trading on Nasdaq Stockholm began on May 19, 2025. The final price per SDR was set at SEK 87.51, with gross proceeds of approximately SEK 39 million. Alvotech aims to become a global leader in biosimilars development and manufacturing, providing better access to high-quality biologics for patients worldwide.

The Company’s expansion includes acquiring Xbrane Biopharma AB’s R&D operations in Sweden. A listing on Nasdaq Stockholm is expected to strengthen Alvotech’s presence in the Nordic and European markets, attracting a broader base of investors. A free SDR conversion period will be offered to shareholders. Alvotech’s commercial partnerships cover markets in the US, Europe, Japan, China, and other countries. For more information, visit the Alvotech website or investor portal.



Read more at GlobeNewswire: Trading in Alvotech’s Shares on Nasdaq Stockholm Commences